Sam Burshtein

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Kinacia was a Victorian biotechnology company established to commercialise a set of discoveries relating to blood clotting and thrombosis emerging from research conducted at Monash University's Australian Centre for Blood Diseases (ACED). Despite technical success (the IP was eventually sold to Astra Zeneca) and targeting a major commercial opportunity, the company was not successful This chapter presents the initial years of the company's history, leading up to a change in the company's leadership taking place in early 2002.
Original languageEnglish
Title of host publicationMeasured success
Subtitle of host publicationinnovation management in Australia
EditorsPeter Cebon
Place of PublicationCarlton, Vic.
PublisherMelbourne University Press
ISBN (Print)9780522855708
Publication statusPublished - 2008

Publication series

NameMUP academic monograph series
PublisherMelbourne University Press


Dive into the research topics of 'Kinacia'. Together they form a unique fingerprint.

Cite this